|
SkinBioTherapeutics PLC- Skin health-focused life sciences company - Says it is not aware of any ‘material commercial or operational’ reason for the fall in its share price on Monday. Adds that it continues to focus on driving sales of its AxisBiotix-Ps probiotic food supplement, which holds a subscriber-retention rate of more than 80%.
Company explains: ‘The marketing and advertising campaign is now very active, using influencers who have psoriasis themselves for the digital campaign and advertising in regional and national newspapers such as the Mail, Telegraph and Metro. The product continues to receive very positive customer feedback and the subscriber retention rate is now >80%. Other pillars of the business, including work with Croda/Sederma are progressing accordingly to plan.’
Current stock price: 19.00 pence, down 13% on Monday
12-month change: down 72%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
